Information Provided By: 
Fly News Breaks for February 10, 2017
ICPT
Feb 10, 2017 | 11:27 EDT
Leerink analyst Joseph Schwartz says he's "not convinced" the endpoint changes raise the probability of success for Intercept Pharmaceuticals' obeticholic acid. It is discouraging that enrolling the 1,400 patient cohort was unattainable in a timely manner, Schwartz tells investors in a research note. The analyst keeps a Market Perform rating on the shares. Intercept is up 5% to $118.59 in late morning trading.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
